



# Validation of Methods for the Determination of Low Molecular Heparin Anti-IIa Activity Assays for Analysis of Enoxaparin


Jamil Hantash, Kathleen Cicero, Lisa Lundberg, Snaehal Gadkari, Hema Desai, George Scott and Chris Beaver

## Introduction

The activity of Enoxaparin is dependent upon its binding to anti-thrombin (AT). Binding induces a conformational change in the molecule which accelerates its inhibitory activity. As LMWH are heterogeneous molecules, it is not possible to quantify them directly; therefore, we report here on the development and validation of chromogenic activity assays for the determination of Enoxaparin using anti-IIa activity in human plasma.

## Materials and methods

The Anti-IIa activity assay is carried out by addition of standards, quality controls and samples to a human anti thrombin III reagent (25µL; 375µL). After mixing, the mixture is allowed to incubate at 37° C for 15 minutes. Then an aliquote removed and additional (200µL) of human anti thrombin III reagent is added and allowed to incubate for 2 minutes. Bovine thrombin is added (200 µL) and allowed to incubate for 2 minutes. Spectrozyme TH substrate (200 µL) is then added and allowed to incubate for 2 minutes. Finally, glacial acid (200 µL) is added to stop the reaction. The plate is then read at 405 and 450 nm



**Figure 1.** Hemostasis process in humans

Source: Majerus, P.W., et al. 1990. In The Pharmacological Basis of Therapeutics, 8th Edition (Gilman, A.G., et al.) pp. 1311-1331, New York, Pergamon Press.


## Results

For the anti-IIa method the calibration range was from 0.0400 to 0.500 IU/mL with a LLOQ of 0.0400 IU/mL. The accuracy ranged from -8.6 to 3.6% and an intra-precision, ranged from 1.9 to 21.3%, an inter-precision ranged from -8.6 to 21.3% and a total error ranged from 4.4 to 22.6%. Dilutional linearity was acceptable for up to 10-fold dilution and no hook effect was observed. Enoxaparin LMWH using anti-IIa is stable in human plasma samples held in polypropylene tubes for 25.5 hours and 24.5 hours at ambient temperature (~25° C) and at approximately 4° C, respectively. Enoxaparin using anti-IIa stability was proven in human plasma stored at approximately 80° C in polypropylene tubes for up to 57 days and for up to 4 freeze/thaw cycles.

Characteristic	Statistic	Nominal Concentration (ng/mL)				
		QC1 0.0400	QC2 0.100	QC3 0.200	QC4 0.400	QC5 0.500
# Results	N	41	41	40	42	42
Accuracy	Mean Bias (%RE)	0.2	1.4	3.6	1.9	-8.6
Precision	Intrabatch (%CV)	21.3	2.8	1.9	2.1	2.5
Total Error	Mean ± Interbatch	22.582	4.200	5.504	4.932	12.890


**Table 1.** Accuracy and precision Summary

Total Error for Precision and Accuracy from LBA Spreadsheet for Enoxaparin Low Molecular Weight Heparin using Anti-IIa in Human Plasma




**Figure 2.** Analytical Performance of Quality Control Samples for the Determination of Enoxaparin Low Molecular Weight Heparin using Anti-IIa in Human Plasma

All values within acceptance criteria: ±20.0% RE for all QC samples



**Figure 3.** Linearity of Dilution and Hook effect for Enoxaparin Low Molecular Weight Heparin using Anti-IIa in Human Plasma



**Figure 4.** Representative Standard Curve of Enoxaparin Low Molecular Weight Heparin using Anti-IIa in Human Plasma

Stability Experiment	Low Concentration (0.1 IU/mL)		High Concentration (0.4 IU/mL)	
	RE (%)	CV (%)	RE (%)	CV (%)
Short Term Stability at room temperature (25.5 hours)	-10	3.99	2.5	1.97
Short Term Stability at 4°C (24.5 hours)	-8.9	2.84	0.75	2.44
Freeze thaw Stability at -20°C (4 cycles)	-9.6	9.99	1.75	1.11
Freeze thaw Stability at -80°C (4 cycles)	-4.8	2.7	-1.75	1.55
Long term Stability at -80°C (25 days)	1	5.09	7	0.404

**Table 2.** Stability of Enoxaparin Low Molecular Weight Heparin using Anti-IIa in Human Plasma

## Conclusions

The validated Chromogenic assays for the determination of Enoxaparin using anti-IIa activity in human plasma successfully met all standard assay-validation parameters and were suitable for use in bioequivalence studies.

## Correspondence

Chris Beaver, PhD  
P: 609.806.4802 F: 609.951.0080 M: 514.791.3935  
christopherjohn.beaver@inventivhealth.com  
http://www.inVentivHealthclinical.com

